Approximately 60 patients suffering breakthrough cancer pain will participate in a clinical trial that compares fentanyl medication with an inhaled medical cannabis product developed by Tetra Bio-Pharma.
Rapid-onset opioids are the standard treatment for breakthrough cancer pain, which comes on quickly and is extremely intense.
Tetra Bio-Pharma said clinical data already shows that its lead drug, PPP001, can bring rapid relief and may even be a faster-acting alternative to opioid fentanyl.
Led by McGill University professor Antonio Vigano, MD, and in collaboration with Sante Cannabis, the study is expected to start in December, with recruitment to follow.
As a prescription drug with a Drug Identification Number, Tetra’s cannabis-based medication will be eligible for insurance coverage and be accessible in pharmacies.